CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
CAMBRIDGE, Mass., May 08, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows:
Bank of America Merrill Lynch 2017 Health Care Conference
| Date: | Wednesday, May 17, 2017 | ||
| Forum: | Panel Discussion on Gene Therapy and Gene Editing | ||
| Time: | 4:40 p.m. ET | ||
| Location: | Las Vegas |
UBS Global Healthcare Conference
| Date: | Monday, May 22, 2017 | ||
| Forum: | Company Presentation and Breakout Session | ||
| Time: | 8:00 a.m. ET | ||
| Location: | New York |
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Cristi Barnett Editas Medicine, Inc. (617) 401-0113 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
